Baricitinib
Sign in to save this workspacePrimary targets: JAK1, JAK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
97.99
Gini
0.616
CATDS
0.014
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Baricitinib. Strongest target: STK38L_NDR2 at 99.4% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | STK38L_NDR2 | 99.4% | 0.6% |
| 2 | JAK1 | 98.1% | 1.9% |
| 3 | TYK2 | 97.3% | 2.7% |
| 4 | JAK2 | 97.2% | 2.8% |
| 5 | STK38_NDR1 | 97.1% | 2.9% |
| 6 | JAK3 | 97.0% | 3.0% |
| 7 | STK22D_TSSK1 | 91.7% | 8.3% |
| 8 | PKA | 90.9% | 9.1% |
| 9 | PKCG | 88.2% | 11.8% |
| 10 | LATS1 | 86.4% | 13.6% |
| 11 | CAMK2D | 82.2% | 17.8% |
| 12 | DAPK1 | 81.9% | 18.1% |
| 13 | ROCK1 | 81.7% | 18.3% |
| 14 | DMPK2 | 81.2% | 18.9% |
| 15 | PKACB | 80.3% | 19.7% |
| 16 | PKACG | 79.9% | 20.1% |
| 17 | ACK1 | 79.5% | 20.5% |
| 18 | PKCD | 76.9% | 23.1% |
| 19 | ROCK2 | 76.5% | 23.5% |
| 20 | P70S6K_RPS6KB1 | 74.7% | 25.3% |
Selectivity landscape
Where Baricitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Baricitinib.
Atlas insights for Baricitinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 2272.34 | |
| ALLOGRAFT_REJECTION | 5309.79 | |
| ANDROGEN_RESPONSE | 1825.95 | |
| ANGIOGENESIS | 792.75 | |
| APICAL_JUNCTION | 5440.49 | |
| APICAL_SURFACE | 645.50 | |
| APOPTOSIS | 5695.83 | |
| BILE_ACID_METABOLISM | 634.07 | |
| CHOLESTEROL_HOMEOSTASIS | 585.31 | |
| COAGULATION | 616.41 | |
| COMPLEMENT | 3136.11 | |
| DNA_REPAIR | 1314.42 | |
| E2F_TARGETS | 4436.81 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 2205.83 | |
| ESTROGEN_RESPONSE_EARLY | 2867.54 | |
| ESTROGEN_RESPONSE_LATE | 2858.56 | |
| FATTY_ACID_METABOLISM | 369.11 | |
| G2M_CHECKPOINT | 4515.96 | |
| GLYCOLYSIS | 2202.39 | |
| HEDGEHOG_SIGNALING | 673.76 | |
| HEME_METABOLISM | 2005.66 | |
| HYPOXIA | 2991.30 | |
| IL2_STAT5_SIGNALING | 2364.26 | |
| IL6_JAK_STAT3_SIGNALING | 4488.10 | |
| INFLAMMATORY_RESPONSE | 3900.38 | |
| INTERFERON_ALPHA_RESPONSE | 735.11 | |
| INTERFERON_GAMMA_RESPONSE | 5174.12 | |
| KRAS_SIGNALING_DN | 912.49 | |
| KRAS_SIGNALING_UP | 2198.07 | |
| MITOTIC_SPINDLE | 4141.80 | |
| MTORC1_SIGNALING | 2634.30 | |
| MYC_TARGETS_V1 | 2647.62 | |
| MYC_TARGETS_V2 | 662.81 | |
| MYOGENESIS | 3351.43 | |
| NOTCH_SIGNALING | 250.34 | |
| OXIDATIVE_PHOSPHORYLATION | 613.04 | |
| P53_PATHWAY | 2633.40 | |
| PANCREAS_BETA_CELLS | 365.73 | |
| PEROXISOME | 934.60 | |
| PI3K_AKT_MTOR_SIGNALING | 6758.18 | |
| PROTEIN_SECRETION | 1759.45 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 212.00 | |
| SPERMATOGENESIS | 1607.40 | |
| TGF_BETA_SIGNALING | 1718.04 | |
| TNFA_SIGNALING_VIA_NFKB | 4097.75 | |
| UNFOLDED_PROTEIN_RESPONSE | 1401.78 | |
| UV_RESPONSE_DN | 3387.28 | |
| UV_RESPONSE_UP | 2766.44 | |
| WNT_BETA_CATENIN_SIGNALING | 1651.57 | |
| XENOBIOTIC_METABOLISM | 1221.07 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.861 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.855 |
| SRR23303752 | — | 0.842 |
| SRR12202498 | — | 0.837 |
| TCGA-FD-A43X-01A-11R-A23W-07 | — | 0.837 |
Annotations
Sign in to read and post annotations.
Loading…